Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma
Launched by THE THIRD AFFILIATED HOSPITAL OF KUNMING MEDICAL COLLEGE. · Oct 15, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to better choose surgical options for patients with stage IA lung adenocarcinoma, a type of lung cancer. The researchers are studying past medical records and CT scans to identify factors that might indicate whether the cancer has spread through the air spaces in the lungs, which can make treatment more complicated. Understanding these factors can help doctors decide on the best surgical approach for each patient.
To participate in this study, individuals must be at least 18 years old and have a specific type of lung nodule (less than 3 cm in size) that has been diagnosed as invasive lung adenocarcinoma through a biopsy. Participants must have had their CT scans done at Yunnan Cancer Hospital within two weeks before their surgery, and it’s important that their scans show no signs of cancer spreading to other parts of the body. If you fit these criteria, this trial could help improve future treatment options for lung cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Preoperative CT images reported that the maximum diameter of pulmonary nodules was less than 3 cm
- • All subjects provided CT imaging obtained from Yunnan Cancer Hospital within a 2-week period prior to surgery
- • Postoperative pathological diagnosis of invasive lung adenocarcinoma
- • Remote metastasis was excluded by preoperative imaging (CT, PET-CT, ultrasound, etc.)
- • Age ≥ 18 years
- Exclusion Criteria:
- • Incomplete collection of medical records, imaging data, or hematology data
- • Preoperative complications of other malignant tumors
- • Unclear correspondence between postoperative pathological report and preoperative CT nodule location
- • Images do not meet analysis conditions due to pulmonary infection or large respiratory motion artifacts
- • Postoperative pathology revealed two or more nodules classified as infiltrating adenocarcinoma
- • Prior lung surgery or preoperative neoadjuvant therapy
About The Third Affiliated Hospital Of Kunming Medical College.
The Third Affiliated Hospital of Kunming Medical College is a leading clinical research institution dedicated to advancing medical knowledge and improving patient care through innovative research initiatives. With a strong commitment to excellence, the hospital integrates clinical practice, education, and research, providing a collaborative environment for healthcare professionals and researchers. It utilizes state-of-the-art facilities and a multidisciplinary approach to conduct rigorous clinical trials, ensuring adherence to ethical standards and regulatory compliance. The hospital aims to contribute to the development of effective therapeutic solutions and enhance health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kunming, Yunnan, China
Patients applied
Trial Officials
Lianhua Ye
Study Director
The Third Affiliated Hospital of Kunming Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported